FDA Staff Not Sold on Broad Olaparib Indication in Metastatic CRPC

(MedPage Today) -- Olaparib (Lynparza) plus abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (CRPC) is only clearly effective in patients with BRCA mutations, FDA staff contended in a briefing document...
Source: MedPage Today Public Health - Category: American Health Source Type: news